Immune-Related Adverse Events for Lung Toxicity - Pneumonitis
Grades severity of pneumonitis secondary to immune checkpoint inhibitor therapy.
Use in adult patients with symptoms of pneumonitis or focal or diffuse inflammation of the lung parenchyma typically identified on CT imaging while on treatment with immune checkpoint inhibitors.
When to Use
Asymptomatic, confined to one lobe of the lung or <25% of lung parenchyma, clinical, or diagnostic observations only
Symptomatic, involves more than one lobe of the lung or 25-50% of lung parenchyma, medical intervention indicated, limiting instrumental ADL
Severe symptoms, hospitalization required, involves all lung lobes or >50% of lung parenchyma, limiting self-care ADL, oxygen indicated
Life-threatening respiratory compromise, urgent intervention indicated (intubation)
Please fill out required fields.
- Nazli Dizman, MD
Have feedback about this calculator?